Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Celltrion
Celltrion
Activities:
Manufacturing
Pharmaceutical
A biopharmaceutical manufacturing company, based in Incheon Metropolitan City, South Korea.
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Wood to expand major biopharmaceutical manufacturing plant in South Korea
Wood will provide detailed engineering design for a new facility that will increase manufacturing capacity of biological medicines by eight million liquid vials per year
Regulatory
Bora and Celltrion team up on oral dosage form drugs
The range of oral dosage form products will be manufactured at Bora’s Zhunan Site, one of the largest pharmaceutical production facilities in Taiwan
Manufacturing
South Korean Celltrion picks Lonza to diversify and expand manufacturing
Existing capacity sits at 190,000 L of drug substance each year
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
NCEs target cancer
As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Media
Asia and Latin America will drive biosimilars growth in next decade, says Visiongain
Established players will focus on monoclonal antibodies and licensing deals
Pharmaceutical
Hikma and CellTrion agree biosimilars distribution for MENA region
Total biologics market in MENA region expected to reach US$500m this year
Pharmaceutical
Hospira and Celltrion to develop and market biogenerics
<p>Hospira, a US supplier of generic injectable pharmaceuticals, has signed a distribution agreement with South Korea-based Celltrion and Celltrion Healthcare.</p>
Subscribe now